Biologics, Creams, and the Safety Factor in Vitiligo (Ep. 44)
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Biologics, Creams, and the Safety Factor in Vitiligo (Ep. 44)
-
ナレーター：
-
著者：
このコンテンツについて
Vitiligo care is finally breaking free from the old routine of steroids and phototherapy. Biologics like JAK inhibitors are driving impressive repigmentation in trials, while ruxolitinib cream made history as the first FDA-approved topical.
But the real headline is safety. A decade of FDA reports on tacrolimus, pimecrolimus, and ruxolitinib shows mostly mild, local side effects — yet a few rare surprises too, from tacrolimus-linked heart rhythm changes to ruxolitinib cases of anemia and pericarditis. None fatal, none disabling — but proof that “topical” doesn’t mean “risk-free,” especially with long-term or large-area use.
We also explore the essentials: how dosing shapes results, how quickly patients improve, and where these treatments are headed.
By 2026–2028, expect longer-lasting repigmentation, fewer steroids, and more personalized options. Until then: cautious optimism, careful reading of labels, and a close eye on what’s next.